NS-136 is a selective muscarinic acetylcholine M4 receptor positive allosteric modulator which is under development for the treatment of schizophrenia and Alzheimer's disease.[1][3][2] It has been found to possess pro-cognitive effects in rodents.[2] The drug is under development by NeuShen Therapeutics.[1][3] As of May 2024, it is in phase 1 clinical trials for schizophrenia and is in the preclinical stage of development for Alzheimer's disease.[1][3] The drug is a small molecule, but its chemical structure does not seem to have been disclosed.[1][3]
| Clinical data | |
|---|---|
| Other names | NS136 |
| Routes of administration | Oral[1] |
| Drug class | Muscarinic acetylcholine M4 receptor positive allosteric modulator[1][2] |
See also
editReferences
edit- ^ a b c d e f "NS 136". AdisInsight. Springer Nature Switzerland AG. 15 May 2024. Retrieved 21 October 2024.
- ^ a b c Yohn SE, Harvey PD, Brannan SK, Horan WP (4 October 2024). "The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia". Frontiers in Psychiatry. 15. Frontiers Media SA. doi:10.3389/fpsyt.2024.1421554. ISSN 1664-0640. PMC 11525114.
- ^ a b c d "Delving into the Latest Updates on NS-136 with Synapse". Synapse. 19 September 2024. Retrieved 21 October 2024.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |